190.65

3.32% 6.12

Repligen Corp (RGEN)

Overview News Price History Option Chain Financials Why RGEN Down? Discussions Forecast

Repligen Corp stock is traded at $190.65, with a volume of 1.57M. It is up +3.32% in the last 24 hours and up +4.97% over the past month. Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Previous Close:

$184.53

Open:

$184.1

24h Volume:

1.57M

Relative Volume:

1.41

Market Cap:

$10.76B

Revenue:

$763.34M

Net Income/Loss:

$51.40M

P/E Ratio:

209.87

EPS:

0.9084

Net Cash Flow:

$104.46M

1W Performance:

+6.99%

1M Performance:

+4.97%

6M Performance:

+63.93%

1Y Performance:

+53.12%

1-Day Range:

$183.75

$192.49

1-Week Range:

$176.22

$192.49

52-Week Range:

$100.99

$192.49

Repligen Corp Stock (RGEN) Company Profile

Name

Repligen Corp

Sector

Healthcare (1068)

Industry

Medical Instruments & Supplies (56)

Phone

(781) 449-9560

Address

41 SEYON STREET, WALTHAM, MA

Employee

2,000

Twitter

@repligen

Next Earnings Date

2026-10-27

Latest SEC Filings

RGEN's Discussions on Twitter

Compare RGEN vs ISRG, BDX, RMD, ALC, MDLN

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGEN Repligen Corp	190.65	10.76B	763.34M	51.40M	104.46M	0.9084
ISRG Intuitive Surgical Inc	399.52	141.14B	11.03B	3.16B	3.22B	8.7251
BDX Becton Dickinson Co	179.23	48.82B	21.37B	1.41B	3.07B	3.9437
RMD Resmed Inc	221.89	32.01B	5.54B	1.52B	1.74B	10.37
ALC Alcon Inc	64.56	31.21B	10.63B	819.00M	1.59B	1.6577
MDLN Medline Inc	34.66	30.41B	29.14B	1.07B	1.05B	1.1956

Repligen Corp Stock (RGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-09-26	Resumed	UBS	Buy
Jul-07-26	Upgrade	The Benchmark Company	Hold → Buy
Jun-02-26	Resumed	Wolfe Research	Outperform
May-15-26	Resumed	RBC Capital Mkts	Outperform
Apr-17-26	Initiated	Rothschild & Co Redburn	Buy
Oct-01-25	Initiated	HSBC Securities	Buy
Sep-22-25	Upgrade	Evercore ISI	In-line → Outperform
Jul-22-25	Resumed	Stephens	Overweight
Jun-24-25	Initiated	Barclays	Overweight
Apr-29-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-18-25	Initiated	Evercore ISI	In-line
Feb-10-25	Initiated	TD Cowen	Buy
Dec-17-24	Initiated	Canaccord Genuity	Hold
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-26-24	Upgrade	Deutsche Bank	Hold → Buy
Jun-18-24	Initiated	Guggenheim	Neutral
Dec-04-23	Downgrade	The Benchmark Company	Buy → Hold
Jul-20-23	Initiated	Wells Fargo	Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
Mar-28-23	Initiated	The Benchmark Company	Buy
Dec-14-22	Initiated	Deutsche Bank	Hold
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Jul-20-22	Initiated	UBS	Buy
Oct-14-21	Initiated	Exane BNP Paribas	Outperform
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Aug-24-20	Reiterated	H.C. Wainwright	Buy
Jun-30-20	Reiterated	H.C. Wainwright	Buy
May-07-20	Reiterated	H.C. Wainwright	Buy
Mar-23-20	Reiterated	H.C. Wainwright	Buy
Nov-15-19	Initiated	Stifel	Buy
Nov-01-19	Upgrade	First Analysis Sec	Outperform → Strong Buy
Oct-15-19	Initiated	SVB Leerink	Outperform
Aug-28-19	Reiterated	First Analysis Sec	Outperform
Aug-23-19	Resumed	Stephens	Overweight
Jul-22-19	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-17-18	Upgrade	CL King	Neutral → Buy
Nov-12-18	Downgrade	CL King	Buy → Neutral
Sep-26-18	Initiated	H.C. Wainwright	Neutral
Dec-08-17	Initiated	Citigroup	Buy
Dec-05-17	Initiated	JP Morgan	Overweight
Nov-13-17	Initiated	CL King	Buy
Oct-02-17	Upgrade	First Analysis Sec	Equal-Weight → Overweight
Jul-21-17	Initiated	William Blair	Outperform
Feb-13-17	Upgrade	Piper Jaffray	Neutral → Overweight

View All

Repligen Corp Stock (RGEN) Latest News

Sep 24, 2026

Form 144 REPLIGEN CORP For: 24 September By Investing.com - Investing.com Nigeria

Sep 24, 2026

Is Repligen Corp (RGEN) Overvalued After 3.3% Rally? GF Value Sa - GuruFocus

Sep 24, 2026

Shares valued at $2.46 million are listed for sale by a Repligen (NASDAQ: RGEN) officer and director. - Stock Titan

Sep 24, 2026